Optical coherence tomography — OCT — is the workhorse of retinal diagnostics. By interfering near-infrared light reflected from different depths of the retina, it builds a cross-sectional image of the layers that matter in macular degeneration, diabetic retinopathy and glaucoma, and it does so non-invasively and in seconds.
The catch is the machine. A conventional OCT scanner is a bench instrument: a broadband light source, an interferometer, a galvanometer scanner and a spectrometer, aligned to micron tolerances and sold at a price that confines it to hospitals and specialist practices. Screening the populations that would benefit most from it — diabetics who need a retinal check every year, patients in places with no ophthalmologist — is exactly where the hardware does not reach.
The route out of that box is photonic integration: putting the interferometer, and with it the optical splitting and combining, onto a silicon photonic chip rather than building it from discrete free-space components. That is a well-established industrial direction — the same fabrication base that made optical transceivers cheap — and several groups have been pushing it toward medical imaging.
Physics World reports that the UK photonics company Siloton has raised £8.4m to speed up development of a portable retinal imaging system. If chip-scale OCT delivers on its promise, the plausible outcome is not a better scanner in the same hospital, but a device that fits in a clinic bag: a retinal camera that a trained technician, rather than an ophthalmologist, can point at an eye and get a diagnostic-quality cross-section from.
The open questions are the usual ones for medtech — regulatory clearance, reimbursement, and whether a compact system retains the axial resolution and imaging depth that clinicians already trust. Those, not the funding, will decide whether portable OCT becomes routine.
